Malaria experts join forces with Novartis to empower local communities to tackle malaria in Africa
June 12, 2012
The Novartis Malaria Initiative is convening global experts from education, government, community health and economics to share best practices and empower local African communities to deliver sustainable malaria healthcare. Roll Back Malaria, the World Health Organization, World Bank and the African Leaders Malaria Alliance are highlighting the urgent need to ensure malaria remains a priority in the current economic climate. Addis Ababa, Ethiopia/Basel, Switzerland, June 26, 2012 – Today, more than 35 countries from across Africa are represented at this year’s National Malaria Control Programme (NMCP) Best Practice Sharing Workshop, entitled ‘Empowering Communities: The Heart of Malaria Control’. Convened by Novartis, this pivotal workshop brings together national and international malaria leaders to discuss key topics and challenges.
This year the workshop is being held in Ethiopia to acknowledge the progress that the country has made in the management of malaria, particularly at the community level. Novartis, with support from the Roll Back Malaria Partnership (RBM), has built a workshop program that addresses the needs of multiple malaria partners and explores how efforts to combat malaria can be expanded. The objective of the workshop is to exchange lessons learned from different models of community case management of malaria among countries and to determine how the gains that have been made can be sustained in the current economic climate.
"We are delighted to launch the 11th NMCP workshop that will address key topics based on the needs of our malaria partners," said Thomas Teuscher, ad interim Executive Director, Roll Back Malaria, hosted by the World Health Organization. "It’s imperative that we listen to the key challenges for all those active in the fight against malaria to ensure that we deliver outputs from the workshop that provide benefits to all the countries and organizations involved."
Malaria funding – sustaining the gains
One of the core sessions will focus on the evolving malaria funding landscape. At a time of global economic uncertainty, partners are calling for malaria to continue to be a priority so that the unprecedented but fragile gains that have been made can be sustained and expanded.
"While it is important that development aid continues to be provided for national malaria control programs, it is also crucial that African countries increase domestic spending on Malaria to ensure we achieve our ambitious target of near zero malaria deaths by 2015," said Dr. Melanie Renshaw, African Leaders Malaria Alliance. "African communities are increasingly empowered to deliver quality integrated healthcare at a local level to ensure a sustainable approach to the management of this disease."
Other topics that will be discussed during the workshop include the evolution of the SMS for Life program (which uses text messages to improve the quality of malaria management by accurately reporting stock levels of antimalarials and other products) and safeguarding the future of African children by delivering child-friendly antimalarial formulations.
NMCP Best Practice Sharing Workshops
Since the first pioneering workshop in 2006, NMCP Best Practice Sharing Workshops have been held in South Africa, Ethiopia, Uganda, Kenya, Tanzania, Mali, Rwanda, Zambia and Benin. These meetings facilitate the exchange of experiences and best practice between countries, highlighting successes and challenges, raising awareness of new initiatives, and discussing practical solutions to the barriers to malaria prevention and treatment.
"The Novartis Malaria Initiative is an active partner in the fight against malaria and we are proud to host the NMCP workshops, which are vital for sharing expertise to improve management of this disease," said Linus Igwemezie, Head of the Novartis Malaria Initiative. "No one organization can combat malaria alone – through combined efforts from all the partners we are able to improve local expertise and skills to ensure long-term health outcomes within communities in Africa".
Groundbreaking and successful projects have emerged from these meetings. For example, as a result of discussions with NMCP managers, Novartis reduced the size of our antimalarial packaging by 40%, making transport and storage more efficient. It was also at a NMCP workshop that participants raised the stock-out issue that led to the SMS for Life program to support more efficient stock management in rural health facilities initially in Tanzania, but now being expanded.
About the Novartis Malaria Initiative
Patients are at the core of the Novartis mission to discover and develop innovative medicines. With this in mind, Novartis has set up a holistic program to fight malaria. Resting on four key pillars – access, treatment, research and development, and capacity building – the Novartis Malaria Initiative is tailored to best meet patient needs. It has become one of the largest access-to-medicine programs in the healthcare industry, measured by the number of patients reached annually.
Since 2001, working with a range of organizations, Novartis has provided 500 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria. Novartis is proud of the remarkable public health milestones these collaborations have helped to achieve. The Novartis Malaria Initiative is engaged in more than 20 public-private partnerships, and together with its partners, and with its continued patient-centric approach, Novartis is committed to the common goal of malaria elimination.
The foregoing release contains certain forward-looking statements that can be identified by terminology such as "objective," "will," "target," "committed," or similar expressions. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Coartem to be materially different from any future results, performance or achievements expressed or implied by such statements. Management’s expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected pacing of artemisinin resistance; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis Media Relations
|Nadine Schecker |
Novartis Media Relations
Novartis Malaria Initiative Communications
+41 61 696 86 33 (direct)
+41 79 682 13 26 (mobile)
- Data on file at Novartis Malaria Initiative. 'Estimated lives saved' is an estimate based on the ratio between annual malaria cases and deaths published in the WHO World Malaria Report, a distribution analysis of the cumulatively supplied Coartem treatments over time and the efficacy rate of Coartem as per published clinical trial data. 2011. Read the article